Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Jan;10(1):32-7.
doi: 10.3904/kjim.1995.10.1.32.

Combination chemotherapy with cyclophosphamide, vincristine, cisplatin and etoposide (COPE) combined with radiotherapy for small cell lung cancer

Y J Nam  1 , C W Choi, S W Shin, K H In, K H Kang, J S Kim, Y H Choi, C Y Kim, M S Choi
Affiliations
Clinical Trial

Combination chemotherapy with cyclophosphamide, vincristine, cisplatin and etoposide (COPE) combined with radiotherapy for small cell lung cancer

Y J Nam et al. Korean J Intern Med. 1995 Jan.

Abstract

Objectives: Small cell lung cancer is sensitive to chemotherapy and radiotherapy. Nevertheless, responses are still short-lived and apparent cure remains for only limited disease patients.

Methods: We combined cyclophosphamide (750 mg/m2 by intravenous infusion at first day) vincristine (2 mg intravenously at third day), cisplatin (20 mg/m2 intravenously for 3 days), and etoposide (100 mg/m2 intravenously for 3 days) with radiotherapy (total 300cGy over 4 weeks in 17 fractions) and treated 39 patients with small cell lung cancer who had received no prior systemic chemotherapy and radiotherapy.

Results: 1) Thirty-nine patients (limited disease: 17 patients, extensive disease 22 patients) were treated and 35 patients were evaluable for response. Overall response rate was 82.8% (complete response 28.6%, partial response 54.2%). 2) The median survival was 52 weeks for all patients and 58 weeks for limited disease and 45 weeks for extensive disease. There was no statically significant survival difference between the two patient groups. The median relapse-free survival time was 48 weeks. 3) Overall, treatment was well tolerated, with granulocytopenia being the most frequent toxicity.

Conclusions: Combination chemotherapy with COPE regimen combined with radiation therapy was effective as a first line therapy for SCLC.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Overall survival rate (Kaplan-Meier).
Fig. 2.
Fig. 2.
Survival rate/Disease extent.
See this image and copyright information in PMC

References

    1. Kim HJ, Jeong MP, Heo DS, Bang YJ, Han SK, Shin YS, Kim NK, Kim KY. Lung cancer in Korea (1980–1984) Korean J Intern med. 1994;46(2):221–228.
    1. Cohen MH, Matthews MJ. Small cell bronchogenic carcinoma: A distinct clinicopathologic entity. Semin Oncol. 1978;5:234–243. - PubMed
    1. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep. 1973;4:31–42. - PubMed
    1. Cohen MH, Creaven PJ, Fossieck BE, Broder LE, Selawry OS, Johnston AV, Williams CL, Minna J. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep. 1977;61:349–354. - PubMed
    1. Holoye PY, Samuels ML, Lanzotti VJ, Smith T, Barkley HT., Jr Combination chemotherapy and radiation therapy for small cell carcinoma. JAMA. 1977;237:1221–1224. - PubMed

Publication types

MeSH terms

Supplementary concepts